3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Colorectal Neoplasms
10
Neoplasm Metastasis
4
Lung Neoplasms
4
Colonic Neoplasms
4
Neoplasms
3
Pancreatic Neoplasms
2
Carcinoma, Renal Cell
2
Solid Tumors
1
Resectable Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Kidney Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
adagrasib
×
1 year
×
Clear all
NCT06026410
2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1
Recruiting
300 enrolled